MagForce AG
MagForce AG operates in the field of nanotechnology-based cancer therapy in Germany and Poland. It offers NanoTherm, a therapy for the treatment of brain tumors; NanoPlan, a software that supports the attending physician in preparing the ideal treatment …
Medical - Instruments & Supplies
DE, Berlin [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 51.52 | 0.19 | 0.13 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 22247143.00 | -16764.46 | 0.08 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Book Value | 100461.34 | 896.74 | -0.89 | |
| Cash | 99900.66 | 3.83 | < 0.005 | |
| Capex | 0.00 | 0.00 | 0.00 | |
| Free Cash Flow | 0.00 | 0.00 | 0.00 | |
| Revenue | 0.00 | 0.01 | 0.01 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 0.00 | 0.38 | 0.38 | |
| Operating Margin | 0.00 | -4.63 | -4.63 | |
| ROA | -100.00 | < 0.005 | 0.00 | |
| ROE | -99.90 | < 0.005 | 0.10 | |
| ROIC | -99.98 | < 0.005 | 0.21 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of MF6.DE is permitted for members.
5
Growth
The "Growth Entry" for the Focus of MF6.DE is permitted for members.
6
Leverage & Liquidity